Latest Clinical News

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed (04-21-2017)

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination... Continue Reading

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma (04-19-2017)

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo... Continue Reading

Tagrisso Approved for Treatment of Certain Lung Cancers (04-18-2017)

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an... Continue Reading

Breast cancer rates increasing among Asian Americans (04-17-2017)

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study.  In contrast to other US racial/ethnic groups, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years. To... Continue Reading

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer (04-13-2017)

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual... Continue Reading

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer (04-12-2017)

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred... Continue Reading

Keytruda Shows Promise in Treatment of Mesothelioma (04-4-2017)

Keytruda (pembrolizumab), an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the... Continue Reading

Niraparib Approved for Ovarian Cancer Maintenance Treatment (04-3-2017)

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based... Continue Reading

FDA Approves Bavencio as First Treatment for Merkel Cell Cancer (03-31-2017)

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (03-28-2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (03-23-2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (03-22-2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also... Continue Reading

Next Page »